Physician profile
Khalid Mahmoud
NPI 1093825432
$3,549.90
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $991 · 2020: $962 · 2021: $1,052 · 2022: $545.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $888.61 | 2019-2022 | |
| Novo Nordisk INC | $547.22 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $461.29 | 2019-2022 | |
| Glaxosmithkline, LLC. | $375.29 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $257.06 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $176.04 | 2019-2021 | |
| Emd Serono, INC. | $164.12 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $130.37 | 2019 | |
| Amarin Pharma, INC. | $106.42 | 2020-2021 | |
| Philips North America LLC | $100.97 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $87.30 | 2022 | |
| Mylan Specialty L.P. | $71.26 | 2019-2022 | |
| Pfizer INC. | $48.72 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $31.37 | 2021 | |
| Lilly USA, LLC | $26.27 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $22.14 | 2022 | |
| Daiichi Sankyo INC. | $21.08 | 2020 | |
| Amgen INC. | $18.18 | 2019 | |
| Sanofi-Aventis U.S. LLC | $16.19 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Khalid Mahmoud listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.